1.Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: a cancer journal for clinicians. 2009;59(4):225–49.
2.Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. The Lancet Oncology. 2014;15(11):1207–14.
3.Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology. 2014;6(5):229–39.
4.Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. Journal of experimental & clinical cancer research: CR. 2012;31:14.
5.Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. Expert opinion on investigational drugs. 2010;19(11):1339–54.
6.Doganay M, Topcu HO, Kokanali MK, Guzel AI, Oskovi A, Akbay S, et al. Krukenberg carcinoma metastasized from stomach resembling mucinous cystadenocarcinoma of the ovary. Journal of experimental therapeutics & oncology. 2015;11(1):23–6.
7.Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. International journal of cancer. 2017;140(11):2451–60.
8.Tortorella L, Vizzielli G, Fusco D, Cho WC, Bernabei R, Scambia G, et al. Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments. Aging and disease. 2017;8(5):677–84.
9.Loughran EA, Leonard AK, Hilliard TS, Phan RC, Yemc MG, Harper E, et al. Aging Increases Susceptibility to Ovarian Cancer Metastasis in Murine Allograft Models and Alters Immune Composition of Peritoneal Adipose Tissue. Neoplasia. 2018;20(6):621–31.
10.Negura L, Dusa CP, Balmus MI, Azoicai D, Negura AM, Marinca MV, et al. BRCA1 5382insC founder mutation has not a significative recurrent presence in Northeastern Romanian cancer patients. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. 2015;56(2):379–85.
11.O’Neill SM, Rubinstein WS, Wang C, Yoon PW, Acheson LS, Rothrock N, et al. Familial risk for common diseases in primary care: the Family Healthware Impact Trial. American journal of preventive medicine. 2009;36(6):506–14.
12.Ruiz-Flores P, Calderon-Garciduenas AL, Barrera-Saldana HA. [Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition]. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 2001;53(1):46–64.
13.La Vecchia C. Ovarian cancer: epidemiology and risk factors. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation. 2017;26(1):55–62.
14.Moszynski R, Zywica P, Wojtowicz A, Szubert S, Sajdak S, Stachowiak A, et al. Menopausal status strongly influences the utility of predictive models in differential diagnosis of ovarian tumors: an external validation of selected diagnostic tools. Ginekologia polska. 2014;85(12):892–9.
15.Daniilidis A, Karagiannis V. Epithelial ovarian cancer. Risk factors, screening and the role of prophylactic oophorectomy. Hippokratia. 2007;11(2):63–6.
16.Shin DW, Choi YJ, Kim HS, Han KD, Yoon H, Park YS, et al. Secondary Breast, Ovarian, and Uterine Cancers After Colorectal Cancer: A Nationwide Population-Based Cohort Study in Korea. Diseases of the colon and rectum. 2018;61(11):1250–7.
17.Koyama T, Mikami Y, Saga T, Tamai K, Togashi K. Secondary ovarian tumors: spectrum of CT and MR features with pathologic correlation. Abdominal imaging. 2007;32(6):784–95.
18.Andresen DM, Pedersen FH, Rasmussen KL. Adenocarcinoma of the small intestine mistaken as a primary ovarian cancer. Archives of gynecology and obstetrics. 2001;265(4):214–5.
19.Gavriilidis P, Ananiadis A, Theodoulidis V, Toskas I, Barbanis S. Ovarian metastasis from breast invasive ductal carcinoma. Hippokratia. 2012;16(4):391.
20.Brogioni S, Viacava P, Tomisti L, Martino E, Macchia E. A special case of bilateral ovarian metastases in a woman with papillary carcinoma of the thyroid. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association. 2007;115(6):397–400.
21.Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, et al. Histological classification of ovarian cancer. Medical electron microscopy: official journal of the Clinical Electron Microscopy Society of Japan. 2003;36(1):9–17.
22.Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, et al. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer treatment reviews. 2015;41(2):136–43.
23.Tebes SJ, Sayer RA, Palmer JM, Tebes CC, Martino MA, Hoffman MS. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecologic oncology. 2007;106(3):482–7.
24.Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. The Cochrane database of systematic reviews. 2013(2):CD008765.
25.Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecologic oncology. 2003;90(3 Pt 2):S8–15.
26.Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecologic oncology. 2003;90(3 Pt 2):S39–44.
27.Kroep JR. Advances in epithelial ovarian cancer therapy. Current pharmaceutical design. 2012;18(25):3735–40.
28.Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, et al. Ovarian cancer: pathology, biology, and disease models. Frontiers in bioscience. 2009;14:2089–102.
29.Erickson BK, Conner MG, Landen CN, Jr. The role of the fallopian tube in the origin of ovarian cancer. American journal of obstetrics and gynecology. 2013;209(5):409–14.
30.Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–64.
31.Lengyel E. Ovarian Cancer Development and Metastasis. The American journal of pathology. 2010;177(3):1053–64.
32.Heitz F, Harter P, Ataseven B, Heikaus S, Schneider S, Prader S, et al. Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy. Annals of surgical oncology. 2018;25(7):2053–9.
33.Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1994;12(9):1748–53.
34.Cannistra SA. Cancer of the ovary. The New England journal of medicine. 1993;329(21):1550–9.
35.Bookman MA, McGuire WP, 3rd, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1996;14(6):1895–902.
36.McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. The New England journal of medicine. 1996;334(1):1–6.
37.Colombo N. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. EJC supplements: EJC: official journal of EORTC, European Organization for Research and Treatment of Cancer [et al]. 2014;12(2):7–12.
38.Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecologic oncology. 2011;122(1):116–20.
39.Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers. 2014;6(3):1769–92.
40.Adams AT, Auersperg N. Transformation of cultured rat ovarian surface epithelial cells by Kirsten murine sarcoma virus. Cancer research. 1981;41(6):2063–72.
41.Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, et al. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. Journal of the National Cancer Institute. 1992;84(8):592–601.
42.Piquette GN, Timms BG. Isolation and characterization of rabbit ovarian surface epithelium, granulosa cells, and peritoneal mesothelium in primary culture. In vitro cellular & developmental biology: journal of the Tissue Culture Association. 1990;26(5):471–81.
43.Nicosia SV, Johnson JH, Streibel EJ. Growth characteristics of rabbit ovarian mesothelial (surface epithelial) cells. International journal of gynecological pathology: official journal of the International Society of Gynecological Pathologists. 1985;4(1):58–74.
44.Spriggs DR, Longo DL. Progress in BRCA-Mutated Ovarian Cancer. The New England journal of medicine. 2018;379(26):2567–8.
45.Mehta A, Vasudevan S, Sharma SK, Kumar D, Panigrahi M, Suryavanshi M, et al. Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India. Cancer management and research. 2018;10:6505–16.
46.Grynberg M, Dagher Hayeck B, Papanikolaou EG, Sifer C, Sermondade N, Sonigo C. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro. Human reproduction. 2018.
47.Girardi F, Barnes DR, Barrowdale D, Frost D, Brady AF, Miller C, et al. Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. Genetics in medicine: official journal of the American College of Medical Genetics. 2018.
48.Shen F, Chen S, Gao Y, Dai X, Chen Q. The prevalence of malignant and borderline ovarian cancer in pre- and post-menopausal Chinese women. Oncotarget. 2017;8(46):80589–94.
49.Merritt MA, Green AC, Nagle CM, Webb PM, Australian Cancer S, Australian Ovarian Cancer Study G. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. International journal of cancer. 2008;122(1):170–6.
50.Abuidris DO, Weng HY, Elhaj AM, Eltayeb EA, Elsanousi M, Ibnoof RS, et al. Incidence and survival rates of ovarian cancer in low-income women in Sudan. Molecular and clinical oncology. 2016;5(6):823–8.
51.Meisel JL, Hyman DM, Jotwani A, Zhou Q, Abu-Rustum NR, Iasonos A, et al. The role of systemic chemotherapy in the management of granulosa cell tumors. Gynecologic oncology. 2015;136(3):505–11.
52.van Altena AM, Karim-Kos HE, de Vries E, Kruitwagen RF, Massuger LF, Kiemeney LA. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. Gynecologic oncology. 2012;125(3):649–54.
53.Doll KM, Puliaev R, Chor J, Roston A, Patel UA, Patel A. Detection of gynecologic cancers in indigent women in an urban inner-city hospital. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2012;22(7):1113–7.
54.Bai H, Sha G, Cao D, Yang J, Chen J, Wang Y, et al. Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Retrospective Study of 164 Cases. Medicine. 2015;94(27):e1121.
55.Kanwal U, Bukhari NI, Rana NF, Rehman M, Hussain K, Abbas N, et al. Doxorubicin-loaded quaternary ammonium palmitoyl glycol chitosan polymeric nanoformulation: uptake by cells and organs. International journal of nanomedicine. 2019;14:1–15.
56.Herzog TJ, Holloway RW, Stuart GC. Workshop: options for therapy in ovarian cancer. Gynecologic oncology. 2003;90(3 Pt 2):S45–50.
57.Zhai J, Luwor RB, Ahmed N, Escalona R, Tan FH, Fong C, et al. Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer. ACS applied materials & interfaces. 2018;10(30):25174–85.
58.Kucukoner M, Isikdogan A, Yaman S, Gumusay O, Unal O, Ulas A, et al. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology. Asian Pacific journal of cancer prevention: APJCP. 2012;13(8):3973–6.
59.Kodaz H, Hacibekiroglu I, Turkmen E, Erdogan B, Elpen C, Uzunoglu S, et al. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer. Tumori. 2015;101(1):36–40.
60.Boisen MM, Lesnock JL, Richard SD, Beriwal S, Kelley JL, Zorn KK, et al. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2016;26(4):626–31.
61.Anfinan N, Sait K, Ghatage P, Nation J, Chu P. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre. Archives of gynecology and obstetrics. 2011;284(3):731–5.
62.Kheiri SA, Kunna A, Babiker AY, Alsuhaibani SA, Ahmed RY, Alsammani MA. Histopathological Pattern and Age Distribution, of Malignant Ovarian Tumor among Sudanese Ladies. Open access Macedonian journal of medical sciences. 2018;6(2):237–41.
63.Iwabuchi H, Sakamoto M, Sakunaga H, Ma YY, Carcangiu ML, Pinkel D, et al. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer research. 1995;55(24):6172–80.
64.Micci F, Haugom L, Abeler VM, Davidson B, Trope CG, Heim S. Genomic profile of ovarian carcinomas. BMC cancer. 2014;14:315.
65.Ramus SJ, Pharoah PD, Harrington P, Pye C, Werness B, Bobrow L, et al. BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer research. 2003;63(2):417–23.
66.Eisenkop SM, Spirtos NM. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecologic oncology. 2001;82(1):143–9.
67.Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014;32(13):1302–8.
68.Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–95.
69.Ata A, Gurses I, Kiykim A, Arican A. Nephrotic syndrome associated with gemcitabine use in a patient with ovarian cancer. The American journal of case reports. 2012;13:268–70.
70.Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. The oncologist. 2002;7 Suppl 5:20–8.
71.Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. Journal of ovarian research. 2009;2:13.
72.Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol. 2005;58(3):308–12.
73.Bast RC, Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer. 2010;116(12):2850–3.
74.Chaudhry P, Srinivasan R, Patel FD, Gopalan S, Majumdar S. Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer. International journal of cancer. 2008;122(8):1716–21.
75.Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, et al. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecologic oncology. 2018;150(2):239–46.
76.Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA–125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(20):4051–8.